Being able to visualize and evaluate the retinal periphery provides a better understanding of the disease status and supports a better treatment decision.
As we approach the end of 2022, members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.
Evidence-based medicine can lead to personalized care, better results for patients
A window into the world of academic retina practice today.
In the 30 years since optical coherence tomography was first described, it has become one of the most widely used technologies for imaging the human eye.
Dr. Ramin Tadayoni discusses the myopia panel at the EURETINA 2021 virtual meeting.
A multifaceted evaluation that includes ultra-widefield imaging can reveal new information and influence treatment decisions.
How long-term intravitreal steroid technology fits into a modern clinic.
Minimizing clinic visits, maximizing use of imaging modalities are key
Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.
In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.
The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.
Rather than speculating in a vacuum about the future of remote monitoring in ophthalmology, it is better to explore how other specialties in medicine adopted and integrated remote monitoring into their care plan frameworks.
A retina specialist discusses impressions and key take away points from patient case.
Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.
Dr. Jorge Calzada shares his methods for treating diabetic macular edema with MicroPulse Laser and anti-VEGF injections.
Nathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, share final thoughts on the changing treatment landscape of neovascular AMD and DME.
In-person and virtual trainings, coupled with the support of local product representatives, are the best ways to ensure retina specialists are set up for success.
Grazia Pertile, MD, discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.
John Pollack, MD, discusses gene therapy advancements in the first installment of his blog for Modern Retina.
Digital exclusive article on red-blue-green ultrawidefield (UWF) imaging
Within 4 months of AEYE-DS's deployment, diabetic retinopathy screening adherence increased from 29 percent to 49 percent.
Dr David Almeida shares two cases of neovascular AMD from his practice, one treatment-naïve and one previously treated, and presents his findings after switching them to faricimab.
Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema.
Safety data on non-clinician-led services have shown a low complication rate
Prompt evaluation and adherence to guidelines for treatment recommendations for lattice retinal degeneration are essential to the preservation of vision and sight.
Foundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.
It is important that the ophthalmic community redouble our efforts in following patients with age-related macular degeneration (AMD) using optical coherence tomography (OCT) to find the early signs of geographic atrophy (GA).